Shariq Shamim ✓

@ShariqShamimMD · Virginia, USA 🇺🇸-🇮🇳 · joined 11 Nov 2017

Interventional Cardiologist, Cath Lab Director #CHIP #CTO #TAVR #PERT #imagefirst tweets personal views ≠medical advise AFMC-O2 उद्यमेनैव हि सिध्यन्ति

22 746Followers

1 425Following

17 082Posts total

179.3KViews on collected posts

Son gönderiler

Shariq Shamim ✓@ShariqShamimMD12 Sep

At this point, Tesla’s Full Self-Driving technology is advanced enough that driving a car feels like a chore. Hardware 4 with FSD 14.X. If you have a hectic commute, try FSD, your stress level will decrease significantly. https://t.co/FDkOfc0IrO

4.7K views · 46 likes · 2 reposts · 6 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD7 Sep

Great summery of trials focused on plaque regression: 4.9K views · 8 likes · 2 reposts · 1 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD7 Sep

🚨 Cardiology dogma says plaque only builds. It never breaks down. Nine imaging trials from 2004 to 2023 prove that dogma wrong. "But the data says otherwise." And no, this is not just theory. This is IVUS, OCT, and NIRS imaging inside real coronary arteries. I am a https://t.

31.8K views · 239 likes · 54 reposts · 22 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD30 Aug

Are we going to start DOAC post TAVR not DAPT? @djc795 12.1K views · 31 likes · 7 reposts · 10 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD30 Aug

Presented at #ESCCongress from @JAMA_current: After #TranscatheterAorticValveImplant, factor Xa inhibitor non–vitamin K antagonist oral anticoagulant monotherapy reduced hypoattenuated leaflet thickening vs acetylsalicylic acid monotherapy. https://t.co/aLY3mdBmL8 https://t.co

14.4K views · 27 likes · 12 reposts · 2 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD29 Aug

@ShariqShamimMD Beg to differ - Why not? Is there any trial evidence showing ARBs are superior to ACEi? All head-to-head trials are non-inferior at best. Post-MI with LV dysfunction / HF: • SAVE (captopril vs placebo): 19% relative reduction in all-cause mortality • AIRE (rami 2.6K views · 16 likes · 3 reposts · 3 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD29 Aug

@ShariqShamimMD I use ARB always exclusively because it’s an easy transition to ARNI 2.6K views · 12 likes · 0 reposts · 0 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD28 Aug

@ShariqShamimMD No RCT trial has ever demonstrated mortality benfit for ARB in heart failure. Conversely huge mortality benefits seen for ACEi in HF RCTs. Trial evidence is much stronger for ACEi than ARB. 5.7K views · 44 likes · 1 reposts · 5 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD28 Aug

Why do we still use ACEi as compared to ARB? Similar if. It same benefits for cardiovascular and renal protection. No one knows who will get ACEi Angioedema. Why not just use ARB only? 87.2K views · 247 likes · 10 reposts · 26 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD28 Aug

More data to support BiVal as default AC during STEMI intervention. Are we all going to move to BiVal from Heparin during STEMI as it’s class IA 2025 ACC/AHA to reduce risk of death? #cardiotwitter #CardioX 4.1K views · 11 likes · 3 reposts · 2 replies Open on X →

Shariq Shamim ✓@ShariqShamimMD28 Aug

In BRIGHT-4 (n=6016 randomized), bivalirudin + a 2-4h infusion ↓ mortality & major bleeding during primary PCI in STEMI c/w UFH (Lancet). At ESC/JACC today, in a prespecified substudy, the survival and bleeding benefits extended to low as well as high bleeding-risk pts. https://t

9.2K views · 50 likes · 12 reposts · 2 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 11 gönderi, 10K–100K takipçi aralığıyla yan yana. geniş kitleye gösteriliyor, ama izleyenlerin azı tepki veriyor.

Medyan görüntülenme5 709bu hesap92410K–100K için medyan

Erişim, %25.10%bu hesap3.62%10K–100K için medyan

Etkileşim, %0.46%bu hesap1.52%10K–100K için medyan

Ölçüt	Bu hesap	10K–100K için medyan	Oran
Gönderi başına medyan görüntülenme	5 709	924	6.18×
Erişim (görüntülenme ÷ takipçi)	25.10%	3.62%	6.93×
Etkileşim oranı	0.46%	1.52%	0.30×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

9.2K28 Aug

4.1K

87.2K

5.7K

2.6K29 Aug

2.6K

14.4K30 Aug

12.1K

31.8K7 Sep

4.9K

4.7K12 Sep

Last 11 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.70%28 Aug

0.39%

0.32%

0.88%

0.45%29 Aug

0.86%

0.29%30 Aug

0.40%

0.99%7 Sep

0.22%

1.14%12 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes52.1%731 in total

Reposts7.5%106 in total

Replies5.6%79 in total

Quotes0.1%1 in total

Bookmarks34.7%487 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Son gönderiler

Aynı büyüklükteki hesaplara karşı

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Benzer hesaplar